Cysteine Protease

Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience

237 views | Jul 27 2021

Marta Krejci et al. found that the course of COVID-19 disease in MM pts was mostly moderate or serious with 56% of hospitalizations and 18% of deaths. [Read the Full Post]

Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours

207 views | Jun 02 2021

Mark R Middleton et al. found that Berzosertib + gemcitabine was well tolerated in patients with advanced solid tumours and showed preliminary efficacy signs. [Read the Full Post]

Identification of mouse cathepsin K structural elements that regulate the potency of odanacatib

798 views | Jan 05 2018

Law S et al. determined and compared the structures of inhibitor-free mouse CatK (mCatK), hCatK and ODN bound to hCatK. [Read the Full Post]